

Oliver Distler

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2656353/oliver-distler-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

424
papers

23,611
citations

78
h-index

140
g-index

504
ext. papers

29,614
ext. citations

5.9
avg, IF

6.61
L-index

#	Paper	IF	Citations
424	Role of synovial fibroblast subsets across synovial pathotypes in rheumatoid arthritis: a deconvolution analysis.. <i>RMD Open</i> , 2022 , 8,	5.9	2
423	Skin biomarkers associated with complex regional pain syndrome (CRPS) Type I: a systematic review.. <i>Rheumatology International</i> , 2022 , 1	3.6	0
422	Detect-and-segment: A deep learning approach to automate wound image segmentation. <i>Informatics in Medicine Unlocked</i> , 2022 , 29, 100884	5.3	7
421	Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study. <i>Indian Journal of Rheumatology</i> , 2022 ,	0.5	1
420	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. <i>Rheumatology</i> , 2022 ,	3.9	1
419	Sarcoidosis - a multisystem disease.. <i>Swiss Medical Weekly</i> , 2022 , 152, w30049	3.1	
418	An Optimized Tissue Dissociation Protocol for Single-Cell RNA Sequencing Analysis of Fresh and Cultured Human Skin Biopsies.. <i>Frontiers in Cell and Developmental Biology</i> , 2022 , 10, 872688	5.7	2
417	Calcineurin inhibitors in systemic sclerosis: a systematic literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X2210923	3.8	
416	Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	12
415	COMPERA 2.0: A refined 4-strata risk assessment model for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021 ,	13.6	7
414	On the Reliability of Suction Measurements for Skin Characterization. <i>Journal of Biomechanical Engineering</i> , 2021 , 143,	2.1	1
413	COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. <i>Rheumatology International</i> , 2021 , 1	3.6	7
412	Progression of patients with Raynaud® phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). <i>Lancet Rheumatology, The</i> , 2021 , 3, e834-e843	14.2	2
411	Temporal trends in pulmonary arterial hypertension: Results from the COMPERA registry. <i>European Respiratory Journal</i> , 2021 ,	13.6	6
410	Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis. <i>European Respiratory Journal</i> , 2021 ,	13.6	2
409	Systemic Sclerosis-Related Myopathy. <i>In Clinical Practice</i> , 2021 , 363-372	0	
408	Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	1

407	Absenteeism and presenteeism in healthcare workers due to respiratory illness. <i>Infection Control and Hospital Epidemiology</i> , 2021 , 42, 268-273	2	7
406	68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e185-e194	14.2	9
405	Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e175-e184	14.2	3
404	Assessment of Bone Mineral Density From a Computed Tomography Topogram of Photon-Counting Detector Computed Tomography-Effect of Phantom Size and Tube Voltage. <i>Investigative Radiology</i> , 2021 , 56, 614-620	10.1	1
403	Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 125	5.7	0
402	No evidence for an effect of working from home on neck pain and neck disability among Swiss office workers: Short-term impact of COVID-19. <i>European Spine Journal</i> , 2021 , 30, 1699-1707	2.7	5
401	Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study. <i>Infection Control and Hospital Epidemiology</i> , 2021 , 1-7	2	2
400	Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2338-2347	9.5	0
399	Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database. <i>Rheumatology</i> , 2021 ,	3.9	1
398	Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1277-1287	9.5	0
397	Dysregulated Expression of Arterial MicroRNAs and Their Target Gene Networks in Temporal Arteries of Treatment-Naïve Patients with Giant Cell Arteritis. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
396	Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScure trial. <i>BMJ Open</i> , 2021 , 11, e048541	3	1
395	Staphylococcus aureus impairs dermal fibroblast functions with deleterious effects on wound healing. <i>FASEB Journal</i> , 2021 , 35, e21695	0.9	3
394	Wound Image Quality From a Mobile Health Tool for Home-Based Chronic Wound Management With Real-Time Quality Feedback: Randomized Feasibility Study. <i>JMIR MHealth and UHealth</i> , 2021 , 9, e26149	5.5	4
393	An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod. <i>Arthritis Research and Therapy</i> , 2021 , 23, 204	5.7	1
392	The Challenge of Very Early Systemic Sclerosis: A Combination of Mild and Early Disease?. <i>Journal of Rheumatology</i> , 2021 , 48, 82-86	4.1	8
391	Bone Mineral Density Quantification from Localizer Radiographs: Accuracy and Precision of Energy-integrating Detector CT and Photon-counting Detector CT. <i>Radiology</i> , 2021 , 298, 147-152	20.5	4
390	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 143-150	2.4	41

389	Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 238-241	2.4	30
388	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 219-227	2.4	33
387	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. <i>Rheumatology</i> , 2021 , 60, 1410-1418	3.9	6
386	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and ExpertsCConsensus. <i>Autoimmunity Reviews</i> , 2021 , 20, 102738	13.6	14
385	COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic.. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 58-65	2.3	6
384	Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. <i>ERJ Open Research</i> , 2021 , 7,	3.5	3
383	Serotonin and Fibrosis. <i>Receptors</i> , 2021 , 231-246		
382	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 96-106	35.1	38
381	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , 2021 , 60, 5028-5041	3.9	8
380	No Evidence for a Decrease in Physical Activity Among Swiss Office Workers During COVID-19: A Longitudinal Study. <i>Frontiers in Psychology</i> , 2021 , 12, 620307	3.4	9
379	The AP-1 Transcription Factor FosL-2 Regulates Autophagy in Cardiac Fibroblasts during Myocardial Fibrogenesis. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
378	Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1720-1730	9.5	3
377	The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort. <i>Swiss Medical Weekly</i> , 2021 , 151, w20528	3.1	0
376	Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	1
375	Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). <i>Chest</i> , 2021 , 160, 678-689	5.3	12
374	A rare disease patient-reported outcome measure: revision and validation of the German version of the Systemic Sclerosis Quality of Life Questionnaire (SScQoL) using the Rasch model. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 356	4.2	0
373	Elevated Fibronectin Levels in Profibrotic CD14 Monocytes and CD14 Macrophages in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2021 , 12, 642891	8.4	2
372	Functional genomics atlas of synovial fibroblasts defining rheumatoid arthritis heritability. <i>Genome Biology</i> , 2021 , 22, 247	18.3	6

371	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and skin score. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	5
370	Individual functions of the histone acetyl transferases CBP and p300 in regulating the inflammatory response of synovial fibroblasts. <i>Journal of Autoimmunity</i> , 2021 , 123, 102709	15.5	1
369	TNF α induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNF α antibodies. <i>Cardiovascular Research</i> , 2021 ,	9.9	1
368	Pain chronification and the important role of non-disease-specific symptoms in patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 34	5.7	2
367	The Hospital Anxiety and Depression Scale in patients with systemic sclerosis: a psychometric and factor analysis in a monocentric cohort. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 131, 34-42	2.2	
366	Diagnostic measures for patients with systemic sclerosis-associated myopathy. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 131, 85-93	2.2	
365	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 131, 124-133	2.2	0
364	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 124-133	2.2	2
363	The Hospital Anxiety and Depression Scale in patients with systemic sclerosis: a psychometric and factor analysis in a monocentric cohort. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 34-42	2.2	3
362	Diagnostic measures for patients with systemic sclerosis-associated myopathy. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 85-93	2.2	1
361	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 724-726	2.4	38
360	Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. <i>PLoS ONE</i> , 2020 , 15, e0232978	3.7	12
359	Serum Biomarkers for Connective Tissue and Basement Membrane Remodeling are Associated with Vertebral Endplate Bone Marrow Lesions as Seen on MRI (Modic Changes). <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
358	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8
357	European consensus statements for interstitial lung disease in systemic sclerosis [Authors Reply]. <i>Lancet Rheumatology</i> , 2020 , 2, e319-e320	14.2	2
356	Validation of the suction device Nimble for the assessment of skin fibrosis in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 128	5.7	2
355	Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1897-1904	9.5	2
354	On-site multi-component intervention to improve productivity and reduce the economic and personal burden of neck pain in Swiss office-workers (NEXpro): protocol for a cluster-randomized controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2020 , 21, 391	2.8	7

353	Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 61-71	2.3	26
352	Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse. <i>British Journal of Pharmacology</i> , 2020 , 177, 4296-4309	8.6	12
351	Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1489-1493	5.3	16
350	Predictors of progression in systemic sclerosis patients with interstitial lung disease. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	52
349	The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. <i>Lancet Rheumatology, The</i> , 2020 , 2, e71-e83	14.2	82
348	Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1123-1125	2.4	3
347	COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 668-669	2.4	93
346	TGF- β -induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. <i>Journal of Clinical Investigation</i> , 2020 , 130, 2347-2363	15.9	24
345	Long noncoding RNA H19X is a key mediator of TGF- β -driven fibrosis. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4888-4905	15.9	19
344	Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 61-71	2.3	12
343	Activated Cardiac Fibroblasts Control Contraction of Human Fibrotic Cardiac Microtissues by a β -Adrenoreceptor-Dependent Mechanism. <i>Cells</i> , 2020 , 9,	7.9	4
342	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. <i>Rheumatology</i> , 2020 , 59, 1684-1694	3.9	9
341	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020 , 19, 102458	13.6	90
340	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. <i>Rheumatology</i> , 2020 , 59, 2016-2023	3.9	5
339	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. <i>Autoimmunity Reviews</i> , 2020 , 19, 102452	13.6	22
338	Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 370-378	2.4	24
337	Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	14
336	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.. <i>Lancet Rheumatology, The</i> , 2020 , 2, e743-e753	14.2	13

335	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. <i>Journal of Heart and Lung Transplantation</i> , 2020 , 39, 1435-1444	5.8	24
334	Chromatin accessibility landscapes of skin cells in systemic sclerosis nominate dendritic cells in disease pathogenesis. <i>Nature Communications</i> , 2020 , 11, 5843	17.4	9
333	Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSICIS trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1478-1484	2.4	21
332	Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study. <i>ACR Open Rheumatology</i> , 2020 , 2, 496-502	3.5	1
331	The AP1 Transcription Factor Fosl2 Promotes Systemic Autoimmunity and Inflammation by Repressing Treg Development. <i>Cell Reports</i> , 2020 , 31, 107826	10.6	13
330	cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis. <i>Rheumatology</i> , 2020 , 59, 3939-3951	3.9	3
329	The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease. <i>Respiratory Research</i> , 2020 , 21, 197	7.3	13
328	The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 1065-1074	5.1	1
327	Response to: Correspondence on Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSICIS trial by Bredemeier. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	
326	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. <i>Arthritis Research and Therapy</i> , 2020 , 22, 257	5.7	4
325	Response to: Riociguat in systemic sclerosis: a potential for disease modification by Jain and Dhir. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	
324	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 963-974	35.1	112
323	Response to: Correspondence on Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension by Iudici. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	
322	Prediction of organ involvement and survival in systemic sclerosis patients in the first 5 years from diagnosis.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 57-65	2.3	2
321	Patient perception of disease burden in diffuse cutaneous systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 66-76	2.3	3
320	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020 , 72, 125-136	9.5	92
319	Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 137-149	9.5	42
318	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 618-625	2.4	30

317	Evaluation of botulinum toxin A injections for the treatment of refractory chronic digital ulcers in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 125, 154-160	2.2	3
316	Impaired micronutrients and prealbumin in patients with established and very early systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 125, 120-126	2.2	
315	Visual assessment of digital ulcers in systemic sclerosis analysed by eye tracking: implications for wound assessment. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 125, 137-139	2.2	
314	Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 125, 161-168	2.2	3
313	Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". <i>Autoimmunity Reviews</i> , 2019 , 18, 102394	13.6	42
312	Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 1009-1017	5.1	23
311	PU.1 controls fibroblast polarization and tissue fibrosis. <i>Nature</i> , 2019 , 566, 344-349	50.4	67
310	Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>Arthritis Research and Therapy</i> , 2019 , 21, 23	5.7	15
309	Olive Leaf Extract Attenuates Inflammatory Activation and DNA Damage in Human Arterial Endothelial Cells. <i>Frontiers in Cardiovascular Medicine</i> , 2019 , 6, 56	5.4	46
308	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1242-1248	2.4	18
307	OTUD6B-AS1 Might Be a Novel Regulator of Apoptosis in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2019 , 10, 1100	8.4	17
306	Oligomeric S100A4 Is Associated With Monocyte Innate Immune Memory and Bypass of Tolerance to Subsequent Stimulation With Lipopolysaccharides. <i>Frontiers in Immunology</i> , 2019 , 10, 791	8.4	17
305	Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2019 , 380, 2518-2528	59.2	532
304	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. <i>RMD Open</i> , 2019 , 5, e000826	5.9	16
303	Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2019 , 21, 76	5.7	5
302	Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study. <i>Rheumatology</i> , 2019 , 58, 1585-1596	3.9	12
301	WNT3a and WNT5a Transported by Exosomes Activate WNT Signaling Pathways in Human Cardiac Fibroblasts. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	34
300	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 648-656	2.4	43

299	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1553-1570	9.5	31
298	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 979-987	2.4	95
297	Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 288-302	8.1	20
296	Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement. <i>Cytokine</i> , 2019 , 117, 41-49	4	13
295	Response to: Can we further SPARKle the SPAR model? By Kavadichanda. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e94	2.4	
294	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1576-1582	2.4	18
293	Identification and Isolation of Cardiac Fibroblasts From the Adult Mouse Heart Using Two-Color Flow Cytometry. <i>Frontiers in Cardiovascular Medicine</i> , 2019 , 6, 105	5.4	11
292	Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients With Systemic Sclerosis. <i>JACC: Cardiovascular Imaging</i> , 2019 , 12, 2273-2276	8.4	1
291	Regulation of Fibroblast Apoptosis and Proliferation by MicroRNA-125b in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 2068-2080	9.5	8
290	TET1 is an important transcriptional activator of TNF α expression in macrophages. <i>PLoS ONE</i> , 2019 , 14, e0218551	3.7	12
289	Experimental Mouse Model of Bleomycin-Induced Skin Fibrosis. <i>Current Protocols in Immunology</i> , 2019 , 126, e88	4	3
288	Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). <i>Arthritis Research and Therapy</i> , 2019 , 21, 217	5.7	20
287	Vascular Mechanisms of Systemic Sclerosis 2019 , 27-37		2
286	Heart non-specific effector CD4 T cells protect from postinflammatory fibrosis and cardiac dysfunction in experimental autoimmune myocarditis. <i>Basic Research in Cardiology</i> , 2019 , 115, 6	11.8	12
285	OP0245 PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC 2019 ,		3
284	SAT0296 FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A SCLERODERMA PATTERN FROM A NON-SCLERODERMA PATTERN 2019 ,		2
283	OP0068 ABATACEPT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS RESULTS OF A PHASE 2 INVESTIGATOR-INITIATED, MULTICENTER, DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL 2019 ,		1
282	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1681-1685	2.4	3

281	F-AzaFol for Detection of Folate Receptor-Positive Macrophages in Experimental Interstitial Lung Disease-A Proof-of-Concept Study. <i>Frontiers in Immunology</i> , 2019 , 10, 2724	8.4	16
280	Response to: Will SPAR be useful in the usual patients with scleroderma? By Chattopadhyay. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e126	2.4	
279	Visualisation of interstitial lung disease by molecular imaging of integrin $\alpha 5 \beta 1$ and somatostatin receptor 2. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 218-227	2.4	18
278	Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure. <i>Arthritis and Rheumatology</i> , 2019 , 71, 805-816	9.5	17
277	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019 , 71, 964-971	9.5	21
276	^{18}F -fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 577-578	2.4	12
275	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019 , 18, 93-106	13.6	63
274	Increased expression of the TNF superfamily member LIGHT/TNFSF14 and its receptors (HVEM and LTR) in patients with systemic sclerosis. <i>Rheumatology</i> , 2019 , 58, 502-510	3.9	4
273	Abnormal esophageal motility during a solid test meal in systemic sclerosis-detection even in very early disease and association with disease progression. <i>Neurogastroenterology and Motility</i> , 2019 , 31, e13480	4	7
272	Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 686-693	5.3	16
271	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2019 , 58, 254-259	3.9	7
270	Does angiotensin and endothelin receptor blockade have an impact on lung function? An analysis from the EUSTAR database. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 119, 154-155	2.2	
269	Cardiac manifestation of polyarteritis nodosa. <i>European Heart Journal</i> , 2018 , 39, 2603	9.5	2
268	Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 744-751	2.4	27
267	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018 , 57, 813-817	3.9	14
266	Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis. <i>Journal of Investigative Dermatology</i> , 2018 , 138, 826-835	4.3	25
265	Location-specific mechanical response and morphology of facial soft tissues. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2018 , 78, 108-115	4.1	18
264	Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 459	2.4	27

263	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 563-570	2.4	31
262	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018 , 57, 370-381	3.9	36
261	Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors. <i>ERJ Open Research</i> , 2018 , 4,	3.5	8
260	Reliability of simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases. <i>Rheumatology</i> , 2018 , 57, 757-759	3.9	42
259	Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	50
258	The emerging application of semi-quantitative and quantitative capillaroscopy in systemic sclerosis. <i>Microvascular Research</i> , 2018 , 118, 113-120	3.7	13
257	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 626-628	2.4	10
256	Functional disability and its predictors in systemic sclerosis: a study from the DeSSciper project within the EUSTAR group. <i>Rheumatology</i> , 2018 , 57, 441-450	3.9	39
255	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 128-132	2.4	17
254	The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 150-158	2.4	32
253	Polyarteritis nodosa. <i>Rheumatology</i> , 2018 , 57, 670	3.9	3
252	Haematopoietic stem cell transplantation in systemic sclerosis. <i>RMD Open</i> , 2018 , 4, e000533	5.9	17
251	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. <i>Arthritis Research and Therapy</i> , 2018 , 20, 17	5.7	60
250	Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1634-1643	9.5	49
249	Evaluation of Tc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2018 , 20, 183	5.7	15
248	The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis. <i>Nature Communications</i> , 2018 , 9, 3259	17.4	60
247	A novel ultra-light suction device for mechanical characterization of skin. <i>PLoS ONE</i> , 2018 , 13, e0201440	3.7	16
246	Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1326-1332	2.4	58

245	Systemic sclerosis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018 , 4, e000782	5.9	53
244	Nodular Regenerative Hyperplasia of the Liver: A Rare Vascular Complication in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2018 , 45, 103-106	4.1	6
243	Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 162-170	9.5	33
242	The impact of slice-reduced computed tomography on histogram-based densitometry assessment of lung fibrosis in patients with systemic sclerosis. <i>Journal of Thoracic Disease</i> , 2018 , 10, 2142-2152	2.6	14
241	Prospective evaluation of the capillaroscopic skin ulcer risk index in systemic sclerosis patients in clinical practice: a longitudinal, multicentre study. <i>Arthritis Research and Therapy</i> , 2018 , 20, 239	5.7	2
240	Gouty arthritis: Can we avoid unnecessary dual-energy CT examinations using prior radiographs?. <i>PLoS ONE</i> , 2018 , 13, e0200473	3.7	3
239	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018 , 272S, 37-45	3.2	33
238	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1829-1834	9.5	6
237	Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 113, 68-75	2.2	3
236	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. <i>Journal of Rheumatology</i> , 2017 , 44, 639-647	4.1	54
235	The transcription factor GLI2 as a downstream mediator of transforming growth factor- β -induced fibroblast activation in SSc. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 756-764	2.4	28
234	Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 244-251	2.4	22
233	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 270-276	2.4	79
232	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1207-1218	2.4	71
231	JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1467-1475	2.4	28
230	Use of biologics and other novel therapies for the treatment of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 469-482	5.1	24
229	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1327-1339	2.4	497
228	Points to consider when doing a trial primarily involving the heart. <i>Rheumatology</i> , 2017 , 56, v12-v16	3.9	5

227	Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. <i>Nature Communications</i> , 2017 , 8, 1130	17.4	155
226	Muscle involvement in systemic sclerosis: points to consider in clinical trials. <i>Rheumatology</i> , 2017 , 56, v38-v44	3.9	19
225	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definition. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 115-120	2.3	49
224	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1897-1905	2.4	230
223	Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. <i>Nature Medicine</i> , 2017 , 23, 938-944	50.5	163
222	Pharyngeal swallowing and oesophageal motility during a solid meal test: a prospective study in healthy volunteers and patients with major motility disorders. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 644-653	18.8	46
221	The epigenetic architecture at gene promoters determines cell type-specific LPS tolerance. <i>Journal of Autoimmunity</i> , 2017 , 83, 122-133	15.5	23
220	Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1941-1948	2.4	96
219	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	288
218	Tie2 as a novel key factor of microangiopathy in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 105	5.7	19
217	RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. <i>Respiratory Medicine</i> , 2017 , 122 Suppl 1, S14-S17	4.17	24
216	Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 257-267	9.5	46
215	Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 11-18	2.3	190
214	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 169-182	2.3	11
213	Innovative Approaches to Clinical Trials in Systemic Sclerosis 2017 , 649-656		
212	Transforming growth factor- β -dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis. <i>European Heart Journal</i> , 2017 , 38, 1413-1425	9.5	107
211	Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 106, 114-121	2.2	1
210	Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS) <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 106, 75-81	2.2	31

209	Activating transcription factor 3 regulates canonical TGF β signalling in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 586-92	2.4	24
208	Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 623-6	2.4	59
207	Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 883-90	2.4	120
206	Sirt1 regulates canonical TGF β signalling to control fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 226-33	2.4	94
205	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 163-9	2.4	68
204	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016 , 68, 167-78	4.7	10
203	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 299-311	9.5	69
202	Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 303-10	2.4	37
201	Tribbles homologue 3 stimulates canonical TGF β signalling to regulate fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 609-16	2.4	24
200	Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 46, 115-23	5.3	53
199	An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. <i>Rheumatology</i> , 2016 , 55, 883-90	3.9	83
198	Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy. <i>Seminars in Immunopathology</i> , 2016 , 38, 87-95	12	61
197	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1285-92	2.4	45
196	Incidence and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. <i>PLoS ONE</i> , 2016 , 11, e0163894	3.7	99
195	Effect of endothelin-1 receptor antagonists on skin fibrosis in scleroderma patients from the EUSTAR database. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 220-225	2.3	2
194	Rapid Growth of Lung Nodules due to Combined Pulmonary Vasculitis, Silicoanthracosis, and Chondrocalcinosis. <i>Canadian Respiratory Journal</i> , 2016 , 2016, 9254374	2.1	1
193	Emerging strategies for treatment of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 186-193	2.3	36
192	Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1743-8	2.4	50

191	Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. <i>European Respiratory Journal</i> , 2016 , 48, 1658-1667	13.6	35
190	Treatment of systemic sclerosis: is there any hope for the future?. <i>RMD Open</i> , 2016 , 2, e000260	5.9	15
189	Efficient therapy of ischaemic lesions with VEGF121-fibrin in an animal model of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1399-406	2.4	3
188	Tocilizumab for systemic sclerosis: implications for future trials. <i>Lancet, The</i> , 2016 , 387, 2580-2581	40	11
187	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2527-39	9.5	92
186	Safety and efficacy of extracorporeal shock wave therapy (ESWT) in calcinosis cutis associated with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34 Suppl 100, 177-180	2.2	7
185	Effects of rituximab in connective tissue disorders related interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34 Suppl 100, 181-185	2.2	19
184	Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. <i>Rheumatology</i> , 2015 , 54, 144-51	3.9	27
183	Cardiomyopathy in murine models of systemic sclerosis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 508-16	9.5	29
182	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1124-31	2.4	76
181	Systemic sclerosis. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15002	51.1	351
180	Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1621-5	2.4	49
179	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015 , 102, 19-24	3.7	11
178	Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1317-24	2.4	24
177	Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1188-94	2.4	267
176	S100A4 amplifies TGF- β -induced fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1748-55	2.4	34
175	Vitamin D receptor regulates TGF- β signalling in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e20	2.4	87
174	Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2015 , 67, 3256-61	9.5	98

173	Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. <i>PLoS ONE</i> , 2015 , 10, e0141911	3.7	51
172	Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. <i>Rheumatology</i> , 2015 , 54, 1454-8	3.9	54
171	Inhibition of casein kinase II reduces TGF β -induced fibroblast activation and ameliorates experimental fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 936-43	2.4	30
170	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. <i>Rheumatology</i> , 2015 , 54, 1262-9	3.9	19
169	Systemic sclerosis in 2014: Advances in cohort enrichment shape future of trial design. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 72-4	8.1	16
168	Management of Scleroderma-Associated Pulmonary Involvement. <i>Current Treatment Options in Rheumatology</i> , 2015 , 1, 51-67	1.3	
167	Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF β signalling. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1408-16	2.4	78
166	Orphan nuclear receptor NR4A1 regulates transforming growth factor- β signaling and fibrosis. <i>Nature Medicine</i> , 2015 , 21, 150-8	50.5	195
165	Outcome Measures for Clinical Trials in Interstitial Lung Diseases. <i>Current Respiratory Medicine Reviews</i> , 2015 , 11, 163-174	0.3	23
164	Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S75-9	2.2	13
163	Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2069-73	2.4	45
162	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1340-9	2.4	444
161	Cardiac arrhythmias and conduction defects in systemic sclerosis. <i>Rheumatology</i> , 2014 , 53, 1172-7	3.9	58
160	Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2087-93	2.4	121
159	Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1264-8	2.4	29
158	The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1232-9	2.4	136
157	Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 191-7	2.4	35
156	Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 624-7	2.4	22

155	Personalized medicine in systemic sclerosis: facts and promises. <i>Current Rheumatology Reports</i> , 2014 , 16, 425	4.9	15
154	Heat shock protein 90 (Hsp90) inhibition targets canonical TGF- β signalling to prevent fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1215-22	2.4	60
153	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 706-14	5.7	40
152	A3.19 miR-193B induces UPA in SSC and contributes to the proliferative vasculopathy via uPAR independent pathways. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A49.2-A49	2.4	
151	Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1880-7	2.4	60
150	Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. <i>Arthritis Research and Therapy</i> , 2014 , 16, 493	5.7	36
149	Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. <i>Science Signaling</i> , 2014 , 7, ra84	8.8	65
148	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. <i>Thorax</i> , 2014 , 69, 428-36	7.3	75
147	Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. <i>Journal of Rheumatology</i> , 2014 , 41, 99-105	4.1	62
146	The nuclear receptor constitutive androstane receptor/NR113 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 3140-50	9.5	12
145	Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. <i>Rheumatology</i> , 2014 , 53, 639-43	3.9	8
144	Visual problem and low back pain as initial manifestation of multiple myeloma complicating pre-existing systemic sclerosis. <i>Journal of the College of Physicians and Surgeons--Pakistan: JCPSP</i> , 2014 , 24 Suppl 1, S29-31	0.7	2
143	2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2737-47		1636
142	Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. <i>Arthritis and Rheumatism</i> , 2013 , 65, 3194-201		131
141	Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?. <i>Current Opinion in Pharmacology</i> , 2013 , 13, 455-62	5.1	12
140	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1747-55	2.4	1109
139	Activation of pregnane X receptor inhibits experimental dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 621-5	2.4	19
138	The Fra-2 transgenic mouse model of systemic sclerosis. <i>Vascular Pharmacology</i> , 2013 , 58, 194-201	5.9	44

137	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. <i>International Journal of Cardiology</i> , 2013 , 168, 871-80	3.2	231
136	Nailfold capillaroscopy in systemic sclerosis: data from the EULAR scleroderma trials and research (EUSTAR) database. <i>Microvascular Research</i> , 2013 , 89, 122-8	3.7	73
135	Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 614-20	2.4	78
134	Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1575-80	2.4	57
133	Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1255-8	2.4	92
132	Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 2039-46	2.4	17
131	Preclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2013 , 25, 679-85	5.3	13
130	Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1217-20	2.4	131
129	Autophagy regulates TNF α -mediated joint destruction in experimental arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 761-8	2.4	201
128	A8.3 Deficit of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNF α Mouse Model. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A58.1-A58	2.4	
127	Skin lesions in anti-Pm-Scl-70 positive systemic sclerosis-dermatomyositis overlap syndrome improve during local PUVA phototherapy. <i>European Journal of Dermatology</i> , 2013 , 23, 730-1	0.8	4
126	Novel Aspects in the Pathophysiology of Peripheral Vasculopathy in Systemic Sclerosis. <i>Current Rheumatology Reviews</i> , 2013 , 9, 237-44	1.6	8
125	Molecular targets for therapy in systemic sclerosis. <i>Fibrogenesis and Tissue Repair</i> , 2012 , 5, S19		12
124	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012 , 64, 351-7	4.7	41
123	Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2012 , 120, 2909-17	2.2	49
122	Inhibition of sumoylation prevents experimental fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1904-8	2.4	25
121	Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1382-7	2.4	80
120	Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. <i>Cytokine</i> , 2012 , 58, 165-8	4	25

119	JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3006-15		89
118	Is there evidence for vasculitis in systemic sclerosis?. <i>Current Rheumatology Reports</i> , 2012 , 14, 516-25	4.9	10
117	Biomarkers of Fibrosis 2012 , 283-290		
116	Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. <i>American Journal of Pathology</i> , 2012 , 181, 1672-80	5.8	25
115	Activation of canonical Wnt signalling is required for TGF- β -mediated fibrosis. <i>Nature Communications</i> , 2012 , 3, 735	17.4	501
114	International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. <i>Arthritis Research and Therapy</i> , 2012 , 14, R2	5.7	13
113	Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. <i>Arthritis Research and Therapy</i> , 2012 , 14, R37	5.7	28
112	Inhibition of activator protein 1 signaling abrogates transforming growth factor β -mediated activation of fibroblasts and prevents experimental fibrosis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1642-52		65
111	Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2724-33		110
110	Ecaterin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 761-7	2.4	147
109	The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1081-7	2.4	33
108	International Classification of Functioning, Disability and Health Core Set construction in systemic sclerosis and other rheumatic diseases: a EUSTAR initiative. <i>Rheumatology</i> , 2012 , 51, 2170-6	3.9	21
107	Innovative antifibrotic therapies in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2012 , 24, 274-80	5.3	43
106	Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 737-45	2.4	46
105	Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1355-60	2.4	199
104	Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 785-9	2.4	63
103	Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1019-26	2.4	65
102	Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1895-9	2.4	27

101	Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 2051-4	2.4	22
100	Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 549-52	2.4	25
99	Role of MicroRNAs in Fibrosis. <i>Open Rheumatology Journal</i> , 2012 , 6, 130-9	0.2	125
98	Epigenetic modifications: novel therapeutic strategies for systemic sclerosis?. <i>Expert Review of Clinical Immunology</i> , 2011 , 7, 475-80	5.1	21
97	Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , 2011 , 154 Suppl 1, S20-33	3.2	38
96	Systemic sclerosis 2011. <i>International Journal of Rheumatology</i> , 2011 , 2011, 308231	2	
95	Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. <i>Journal of Cellular and Molecular Medicine</i> , 2011 , 15, 756-62	5.6	38
94	Emerging targeted therapies in scleroderma lung and skin fibrosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011 , 25, 843-58	5.3	9
93	Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. <i>Current Rheumatology Reports</i> , 2011 , 13, 21-7	4.9	32
92	Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 800-9		63
91	Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 1396-404		92
90	Induction of apoptosis in circulating angiogenic cells by microparticles. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2067-77		34
89	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1178-82	2.4	24
88	Inhibition of glycogen synthase kinase 3 induces dermal fibrosis by activation of the canonical Wnt pathway. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 2191-8	2.4	82
87	Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. <i>Arthritis Research and Therapy</i> , 2011 , 13, 114	5.7	6
86	Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1304-10	2.4	97
85	Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2011 , 38, 2419-27	4.1	2
84	The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1320-6	2.4	45

83	Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1074-9	2.4	51
82	Platelet-derived serotonin links vascular disease and tissue fibrosis. <i>Journal of Experimental Medicine</i> , 2011 , 208, 961-72	16.6	190
81	Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1197-202	2.4	17
80	Is there a role for TNF α antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, S40-5	2.2	54
79	Promoter hypermethylation of the anti-fibrotic gene soxs-3 by TGF β as novel mechanism in the pathogenesis of SSc. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, A26-A26	2.4	
78	Activation of Hedgehog signalling plays a crucial role in the pathogenesis of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, A27-A27	2.4	
77	Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1360-3	2.4	27
76	5-HT release from platelets and activation of 5-HT _{2B} play a crucial role for development of fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, A26-A27	2.4	1
75	Vascular disease in systemic sclerosis. <i>International Journal of Rheumatology</i> , 2010 , 2010, 714172	2	4
74	Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. <i>Journal of Rheumatology</i> , 2010 , 37, 105-15	4.1	29
73	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1809-15	2.4	721
72	Promising anti-fibrotic approaches for future treatment of systemic sclerosis. <i>Current Rheumatology Reviews</i> , 2010 , 6, 305-8	1.6	
71	Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. <i>Current Rheumatology Reviews</i> , 2010 , 6, 138-144	1.6	21
70	The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 280-90		83
69	Evaluation of the efficacy and safety of tergruride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2010 , 62, 291-300		21
68	Decreased lymphatic vessel counts in patients with systemic sclerosis: association with fingertip ulcers. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1513-22		16
67	MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1733-43		409
66	Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3467-76		51

65	Animal models of systemic sclerosis: prospects and limitations. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2831-44		113
64	Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?. <i>Swiss Medical Weekly</i> , 2010 , 140, w13050	3.1	21
63	Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2010 , 28, S47-52	2.2	6
62	Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2009 , 36, 2356-61	4.1	32
61	Stiff skin syndrome: evidence for an inflammation-independent fibrosis?. <i>Rheumatology</i> , 2009 , 48, 849-53.9		12
60	Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. <i>Circulation</i> , 2009 , 120, 2367-76	16.7	85
59	Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 4185-91	5.6	8
58	Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 219-24		162
57	The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1129-36		91
56	Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1519-29		87
55	Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2009 , 60, 3168-79		31
54	Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 3663-75		13
53	Mechanisms of vascular damage in systemic sclerosis. <i>Autoimmunity</i> , 2009 , 42, 587-95	3	57
52	Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2009 , 11, 2205.7		73
51	Animal Models of Scleroderma: From Cellular and Molecular Mechanisms to Novel Antifibrotic Strategies 2009 , 57-75		
50	Novel treatment approaches to fibrosis in scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2008 , 34, 145-59; vii	2.4	7
49	Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. <i>FASEB Journal</i> , 2008 , 22, 2214-22	0.9	169
48	Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 160-4		2

47	Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1475-84		103
46	The controversial role of tumor necrosis factor alpha in fibrotic diseases. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2228-35		78
45	Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2553-64		88
44	Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2538-42		36
43	Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 867-75		45
42	The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2845-53		77
41	Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 311-22		317
40	Analysis of vascular gene expression in arthritic synovium by laser-mediated microdissection. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1094-105		25
39	Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1087-93		164
38	Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2755-64		134
37	Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3564-74		69
36	Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 4203-15		139
35	The role of membrane lipids in the induction of macrophage apoptosis by microparticles. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007 , 12, 363-74	5-4	52
34	Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 836	2-4	13
33	Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. <i>Arthritis Research and Therapy</i> , 2007 , 9, 223	5-7	148
32	Regulation of eicosanoid production in peripheral blood mononuclear cells from patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2007 , 9, P13	5-7	78
31	How does endothelial cell injury start? The role of endothelin in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2007 , 9 Suppl 2, S2	5-7	104
30	Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2007 , 9 Suppl 2, S3	5-7	105

29	Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease--insights and potential therapeutic implications. <i>Nature Clinical Practice Rheumatology</i> , 2007 , 3, 43-51		26
28	Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. <i>Arthritis and Rheumatism</i> , 2006 , 54, 214-25		81
27	Technology insight: gene transfer and the design of novel treatments for rheumatoid arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 153-62		7
26	The potential of adiponectin in driving arthritis. <i>Journal of Immunology</i> , 2006 , 176, 4468-78	5.3	236
25	Microparticles as mediators of cellular cross-talk in inflammatory disease. <i>Autoimmunity</i> , 2006 , 39, 683-90		131
24	Antisense strategies in degenerative joint diseases: sense or nonsense?. <i>Advanced Drug Delivery Reviews</i> , 2006 , 58, 285-99	18.5	13
23	The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. <i>Journal of Investigative Dermatology</i> , 2005 , 124, 92-8	4.3	64
22	Nucleofection: a new, highly efficient transfection method for primary human keratinocytes*. <i>Experimental Dermatology</i> , 2005 , 14, 315-20	4	40
21	Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 856-64		103
20	Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3337-48		179
19	Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3783-91		51
18	The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 2892-7	11.5	336
17	Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways. <i>Molecular Pharmacology</i> , 2004 , 65, 389-99	4.3	21
16	Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 10-23		83
15	Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1468-76		133
14	Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. <i>Circulation Research</i> , 2004 , 95, 109-16	15.7	248
13	Minimum information about a microarray experiment: comment on the editorial by Firestein and Pisetsky. <i>Arthritis and Rheumatism</i> , 2003 , 48, 861; author reply 862		2
12	Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1639-46		39

11	The molecular control of angiogenesis. <i>International Reviews of Immunology</i> , 2002 , 21, 33-49	4.6	48
10	Physiologically low oxygen concentrations in fetal skin regulate hypoxia-inducible factor 1 and transforming growth factor-beta3. <i>FASEB Journal</i> , 2002 , 16, 411-3	0.9	64
9	Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. <i>Circulation</i> , 2002 , 106, 2184-7	16.7	476
8	Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. <i>Arthritis Research</i> , 2002 , 4, R11		192
7	Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1865-75		36
6	Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2665-78		141
5	Gene transfer of protective cytokines in rheumatoid arthritis. <i>Advances in Experimental Medicine and Biology</i> , 2001 , 495, 231-40	3.6	
4	HLA-DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2005-10		56
3	Activation of the IL-4 STAT pathway in rheumatoid synovium. <i>Journal of Immunology</i> , 2000 , 164, 3894-903	3.3	33
2	Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999 , 42, 389-92		81
1	Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. <i>Journal of Scleroderma and Related Disorders</i> , 239719832110644 ^{2,3}		1